PIB Headquarters
PIBβS BULLETIN ON COVID-19
Posted On:
23 AUG 2021 8:14PM by PIB Delhi
- 58.25 Crore vaccine doses have been administered so far under Nationwide Vaccination Drive
- 25,072 new cases in the last 24 hours; lowest in 160 days
- Active cases account for 1.03% of total cases; lowest since March 2020
- India's Active caseload stands at 3,33,924; lowest in 155 days
- Recovery Rate increases to 97.63%; Highest since March 2020
- 44,157 recoveries in the last 24 hours increases Total Recoveries to 3,16,80,626
- Weekly Positivity Rate (1.91%) less than 3% for last 59 days
- Daily positivity rate (1.94%) less than 3% for last 28 days
- 50.75 crore Total Tests conducted so far(Total)
|
Β
Β
#Unite2FightCorona#IndiaFightsCorona
Β
Β
PRESS INFORMATION BUREAU
MINISTRY OF INFORMATION & BROADCASTING
GOVERNMENT OF INDIA
Β
COVID-19 Update
Indiaβs Cumulative COVID-19 Vaccination Coverage exceeds 58.25 Cr
Recovery Rate (97.63%) at its highest since March 2020
25,072 New Cases reported in the last 24 hours
India's Active Caseload (3,33,924) lowest in 155 days
Active cases constitute 1.03% of total cases; lowest since March 2020
Daily Positivity Rate (1.94%) less than 3% for last 28 days
Indiaβs COVID-19 vaccination coverage has surpassed the cumulative figure of 58.25 Cr (58,25,49,595) as per provisional reports till 8 am today. This has been achieved through 64,69,222 sessions.
The break-up of the cumulative figure as per the provisional report till 8 am today includes:
Β
|
HCWs
|
1st Dose
|
1,03,53,405
|
|
2nd Dose
|
82,15,000
|
|
FLWs
|
1st Dose
|
1,83,04,397
|
|
2nd Dose
|
1,25,74,264
|
|
Age Group 18-44 years
|
1st Dose
|
21,69,00,386
|
|
2nd Dose
|
1,94,77,956
|
|
Age Group 45-59 years
|
1st Dose
|
12,26,16,599
|
|
2nd Dose
|
4,87,88,970
|
|
Over 60 years
|
1st Dose
|
8,33,38,747
|
|
2nd Dose
|
4,19,79,871
|
|
Total
|
58,25,49,595
|
Β
The Union Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country.
The recovery of 44,157 patients in the last 24 hours has increased the cumulative tally of recovered patients (since the beginning of the pandemic) to 3,16,80,626.
Consequently, Indiaβs recovery rate stands at 97.63%, the highest since March 2020.
Β
Sustained and collaborative efforts by the Centre and the States/UTs continue the trend of less than 50,000 Daily New Cases that is being reported for fifty-seven consecutive days now.
25,072 new cases were reported in the last 24 hours, this is lowest in 160 days.
High recoveries and a low number of new cases have subsided the Active Caseload to 3,33,924 which is at its lowest in 155 days. Active cases presently form only 1.03% of the country's total Positive Cases which is the lowest since March 2020.
The testing capacity across the country continues to be expanded. The last 24 hours saw a total of 12,95,160 tests being conducted. India has so far conducted over 50.75 Cr (50,75,51,399) cumulative tests.
While testing capacity has been enhanced across the country, Weekly Positivity Rate at 1.91% remains less than 3% for the last 59 days now. The Daily Positivity rate also stands at 1.94%. The daily Positivity rate has remained below 3% for the last 28 days and below 5% for 77 consecutive days now.
Details: https://pib.gov.in/PressReleseDetail.aspx?PRID=1748170
Β
COVID-19 Vaccination Update
More than 57.05 Crore vaccine doses provided to States/UTs
More than 3.44 Crore balance and unutilized vaccine doses still available with States/UTs
Β
As part of the nationwide vaccination drive, Government of India has been supporting the States and UTs by providing them COVID Vaccines free of cost. In the new phase of the universalization of the COVID19 vaccination drive, the Union Government will procure and supply (free of cost) 75% of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.
Β
|
Β
VACCINE DOSES
|
Β
(As on 23 August 2021)
|
|
Β
SUPPLIED
|
Β
57,05,07,750
|
|
Β
PIPELINE
|
Β
13,34,620
|
|
Β
BALANCE AVAILABLE
Β
|
Β
3,44,06,720
|
Β
More than 57.05 crore (57,05,07,750) vaccine doses have been provided to States/UTs so far through Govt of India (free of cost channel) and through direct state procurement category. Further, 13,34,620 doses are in the pipeline.
More than 3.44 Cr (3,44,06,720) balance and unutilized COVID Vaccine doses are still available with the States/UTs to be administered.
Details: https://pib.gov.in/PressReleseDetail.aspx?PRID=1748166
Β
Digital Covid-19 Vaccination Certificates provided to Clinical Trial Participants of COVISHIELD and COVAXIN through Co-WIN
Β
Indian Council of Medical Research (ICMR) in partnership with Serum Institute of India (SII) had conducted phase II/III bridging studies of COVISHIELD from August 2020. Phase III efficacy clinical trials for COVAXIN were also conducted by Bharat Biotech International Limited (BBIL) from November 2020. The Union Ministry of Health and Family Welfare had received several requests from the trial participants for digital vaccination certificates through Co-WIN.
Details: https://pib.gov.in/PressReleseDetail.aspx?PRID=1748301
Β
Indian Scientist Partners with BRICS Group to Setup Network of Genomic Surveillance and Study the Overlap of SARS-CoV-2 with tuberculosis
Β
Department of Biotechnology, Ministry of Science and Technology, Government of India in collaboration with BRICS countries is implementing SARS-CoV-2 NGS-BRICS consortium and multi centric programme to study the impact of severe COVID-19 conditions on TB patients.
The SARS-CoV-2 NGS-BRICS consortium is an interdisciplinary collaboration to advance COVID-19 health-relevant knowledge and to contribute to improvements in health outcomes. The consortium will accelerate the translation of genomic data leading to clinical and public health research and interventions from clinical and surveillance samples by utilising the high-end genomic technologies, and epidemiologic and bioinformatics tools for future use in diagnostic assays and tracking transmission dynamics of COVID-19 and other viruses. The Indian team consists from National Institute of Biomedical Genomics (Professor Arindam Maitra, Professor Saumitra Das, Dr Nidhan K Biswas), Centre for DNA Fingerprinting and Diagnostics (Dr Ashwin Dalal) and Indian Institute of Science (Dr Mohit K Jolly) along with National Laboratory for Scientific Computation - LNCC/MCTI (Dr Ana Tereza Ribeiro de Vasconcelos) from Brazil, Skolkovo Institute of Science and Technology (Professor GeorgiiBazykin) from Russia, Beijing Institute of Genomics, Chinese Academy of Sciences (Professor Mingkun Li) from China and University of KwaZulu-Natal (Professor Tulio de Oliveira) from South Africa will participate in this consortium.
Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1748265
Β
Important Tweets
Β
*********
MV/AS
(Release ID: 1748351)
Visitor Counter : 1133